GenVec - GNVC Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GenVec - GNVC

GNVC 7.193

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Savant	1/11/2017 11:52:11 AM
	Read Replies (1) of 106

GenVec, Inc. (NASDAQ: GNVC), a clinical-stage gene delivery company, announced today that its chief scientific officer, Douglas E. Brough, will present a talk entitled "AdenoVerse(TM) platform for translational development of innovative gene and cell therapies" during the Biotech Showcase at the upcoming Phacilitate Cell & Gene Therapy World 2017 Conference in Miami, Florida. Dr. Brough's presentation will highlight the utility of the AdenoVerse technology platform for gene editing and cell therapy approaches as well as its potential to facilitate other gene-delivery based therapeutics and vaccines from the laboratory bench into the clinic. Dr. Brough's presentation is scheduled for Wednesday, January 18, 2017 at 10:50 a.m. EST; and the slides will be posted at genvec.com.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next